Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of BLU-5937 in adults with refractory or unexplained chronic cough
CTR20240965Phase 3Terminated
- Sponsor
- BELLUS Health Inc.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of camlipixant in refractory chronic cough (RCC), chronic idiopathic cough (CIC), sponsored by BELLUS Health Inc.. Started Dec 2024; status: terminated.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)
Beyond the preview
Go deeper on CTR20240965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240965.